<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16171">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02896361</url>
  </required_header>
  <id_info>
    <org_study_id>SJM-CIP-10125</org_study_id>
    <nct_id>NCT02896361</nct_id>
  </id_info>
  <brief_title>Burst Optimized Stimulation Study</brief_title>
  <acronym>BOSS</acronym>
  <official_title>Burst Optimized Stimulation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medizinische Einrichtungen der Universität Düsseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Duisburg GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NKO Sint-Augustinus Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This purpose of this study is to evaluate the therapeutic efficacy of burst microdosing
      stimulation paradigms in patients with chronic pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, randomized, double-blinded crossover study designed to
      compare conventional burst stimulation parameters to two different burst microdosing
      paradigms.

      Subjects will be randomized 1:1:1 to one of the three groups. Each group will evaluate all 3
      stimulation paradigms in different order.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS) for pain</measure>
    <time_frame>From enrollment, assessed every 2 weeks for a total of 6 weeks</time_frame>
    <description>Standard evaluation of pain intensity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>From enrollment, assessed every 2 weeks for a total of 6 weeks</time_frame>
    <description>Quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject preference</measure>
    <time_frame>assessed 6 weeks after baseline at the last follow up visit</time_frame>
    <description>questionnaire to identify preferred stimulation paradigm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction</measure>
    <time_frame>From enrollment, assessed every 2 weeks for a total of 6 weeks</time_frame>
    <description>questionnaire on satisfaction with current therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>through study completion, an average of 6 weeks</time_frame>
    <description>monitoring of adverse events occurring during the study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Stimulation order 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stimulations delivered in following order:
Standard burst
Burst Microdosing 1
Burst Microdosing 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stimulation order 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stimulations delivered in following order:
Burst Microdosing 1
Burst Microdosing 2
Standard burst</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stimulation order 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stimulations delivered in following order:
Burst Microdosing 2
Standard burst
Burst Microdosing 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol</intervention_name>
    <description>Stimulation parameters are reprogrammed from original values to study defined ones</description>
    <arm_group_label>Stimulation order 1</arm_group_label>
    <arm_group_label>Stimulation order 2</arm_group_label>
    <arm_group_label>Stimulation order 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has been implanted with a commercially available SJM spinal cord stimulator
             for controlling chronic intractable pain associated with back and/or leg pain;

          -  Subject has been exclusively using burst stimulation for at least three months;

          -  Subject is 18 years of age or older;

          -  Subject's pain-related medication regimen was stable in the 4 weeks prior to the
             screening evaluation;

          -  Subject agrees not to add or increase pain-related medication from enrollment through
             the study duration;

          -  Subject is willing to cooperate with the study requirements including compliance with
             the regimen and completion of all office visits;

        Exclusion Criteria:

          -  Subject is currently participating in a clinical investigation study that includes an
             active treatment arm;

          -  Subject is currently receiving, applying or considering seeking workers compensation,
             or is involved in disability litigation;

          -  Subject has a non SJM neuromodulation device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lalit Venkatesan, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>St. Jude Medical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Filippo Agnesi, Ph.D.</last_name>
    <phone>19725264860</phone>
    <email>FAgnesi@sjm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lalit Venkatesan, Ph.D.</last_name>
    <phone>19723098522</phone>
    <email>LVenkatesan@sjm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NKO Sint-Augustinus</name>
      <address>
        <city>Antwerpen</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Duisburg GmbH</name>
      <address>
        <city>Duisburg</city>
        <state>North Rhine-Westphalia</state>
        <zip>47055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Einrichtungen der Universität Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <state>North Rhine-Westphalia</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katja Poggel-Kramer</last_name>
      <phone>+49 211 81-16058</phone>
      <email>Katja.Poeggel-Kraemer@med.uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Larissa Soth</last_name>
      <phone>+49 211 81-16058</phone>
      <email>Larissa.Soth@med.uni-duesseldorf.de;</email>
    </contact_backup>
    <investigator>
      <last_name>Jan Vesper, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 6, 2016</lastchanged_date>
  <firstreceived_date>September 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
